In a multivariate analysis, HER2 morphometric signature was an independent predictor of prolonged DMFS post‐adjuvant anti‐HER2 therapy when adjusted for tumour size, LN status and LVI and HER2 IHC score (HR: 0.4, p = 0.026, 95% CI: 0.18–0.89). The gene discussed is ERBB2; the disease is neoplasm.